ArticleCureus2025
Short-Term Follow-Up Study on the Efficacy and Safety of Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Venous Occlusions.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim This study aimed to assess the short-term safety and efficacy of intravitreal bevacizumab in the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO). Methods A prospective interventional study was conducted from July to December 2023, involving 30 patients with ME due to RVO. Intravitreal bevacizumab (1.25 mg/0.05 mL) was administered every 4-6 weeks. Follow-up evaluations included comprehensive ophthalmic examinations and central retinal thickness (CRT) measurements using optical coherence tomography, performed at baseline and throughout the six-month follow-up. Results The study included 30 patients with a mean age of 55.3 ± 10.21 years. Baseline CRT was 568.53 ± 156.29 µm, which significantly reduced to 309.53 ± 89.11 µm after six months. Best-corrected visual acuity (BCVA) improved from 1.14 ± 0.38 logMAR at baseline to 0.53 ± 0.19 logMAR at six months (p < 0.001). BCVA improvement was observed in 86.5% of patients. A gain of more than three lines was noted in 36.6% (n = 11), two or more lines in 46.6% (n = 14), and one line in 3.33% (n = 1). On average, patients received three injections (range: 1-3). No improvement was seen in 10% (n = 3), while deterioration occurred in 3.33% (n = 1). Conclusion Intravitreal bevacizumab appears to be a safe and effective short-term treatment for reducing ME and improving visual acuity in patients with RVO, based on outcomes observed at a tertiary referral eye hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.